FDA Takes Another Step to Streamline Biosimilar Development with Expanded Use of Non-U.S.-Licensed Comparator Products

Start
Our FDA: Drug & Device Team explores the Food and Drug Administration’s updated draft guidance that eases biosimilar development by allowing greater use of non-U.S.-licensed comparator products in clinical studies….
By: Alston & Bird
Previous Story

Wrongful Death in California Accidents: Do You Have a Claim?

Next Story

M&A Discovery in the AI Era: Generative AI Communications and Outputs May Become Litigation Ammunition